Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial
Johann S. de Bono(Royal Marsden NHS Foundation Trust), Ulrik Lassen(Rigshospitalet), Jeffrey Yachnin(Karolinska University Hospital), Kristian Windfeld(Genmab (Denmark)), Fiona Thistlethwaite(The Christie NHS Foundation Trust), Nicole Concin(Innsbruck Medical University), David S. Hong(The University of Texas MD Anderson Cancer Center), Joo Ern Ang(Royal Marsden NHS Foundation Trust), James Spicer(Guy's Hospital), Brian M. Slomovitz(Mount Sinai Medical Center), Ruth Plummer(Freeman Hospital), Robert H. Jones(Clinical Research Institute), Dearbhaile Catherine Collins(Cork University Hospital), Srinivas Ghatta(Genmab (United States)), Martin Förster, Dorte Nielsen(University of Copenhagen), Hendrik‐Tobias Arkenau(Sarah Cannon Research Institute), Emma Dean(University of Manchester), Jean-Pascal Machiels(Cliniques Universitaires Saint-Luc), Reshma Rangwala(Genmab (United States))
Cited by 228
Related Papers
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma
|International Journal of Gynecological Cancer|2020|1.9k